A microscope preparation of Gram-stained pus from a case of gonorrhoea. Credit: Graham Beards / Wikimedia.

Intravacc has received a contract worth $14.6m from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). 

Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Named NGoXIM, the NG vaccine is based on gonococcal OMVs merged with sustained-release microspheres comprising recombinant human IL-12.

Intended for intranasal administration, NGoXIM was demonstrated to be effective in animal models and elicited a durable and cross-protective immune response in proof-of-concept (PoC) studies. 

The company will create a comprehensive manufacturing process for NGoXIM to generate batches of the vaccine that are Good Manufacturing Practices-compliant. 

Additionally, it will work on non-clinical toxicity (TOX) and Clinical Trial Material batch to conduct a Phase I clinical trial of the vaccine in healthy adult subjects. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This trial will evaluate the safety of the vaccine and generate efficacy data. 

Therapyx will develop and manufacture the IL-12-containing microspheres in the vaccine called GneX12.

Intravacc CEO Dr Jan Groen said: “Together with our sub-contractor Therapyx, we are honoured that NIH and NIAID have awarded us this contract, allowing both of us to demonstrate the safety and tolerability of our intranasal gonorrhoea vaccine candidate, NGoXIM (Avacc 11).”

This contract with base and options is backed by NIH/NIAID’s Department of Health and Human Services.

A sexually transmitted disease, gonorrhoea is caused by the NG bacteria. 

At present, there exists no effective vaccine available to treat gonorrhoea, and the disease repeatedly spreads without developing protective immunity. 

Additionally, antibiotic resistance is very prevalent for the NG bacterium.